Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 41 | ECE2016 | Next issue

18th European Congress of Endocrinology

Guided Posters

Diabetes (2)

ea0041gp90 | Diabetes (2) | ECE2016

Assessment of metabolic markers (myostatin, IGF-1), associated with the state of the lean component in young adults with type 1 diabetes

Dydyshka Yuliya , Shepelkevich Alla

Background and aims: There is compelling evidence that the decline in appendicular muscle mass is a poor prognostic factor for the development of chronic complications of diabetes. In addition to chronic hyperglycemia, reduction of muscle component may be determined by metabolic disorders. Therefore, the aim of study was to assess the possible links between serum myostatin, IGF-1 and a reduction in muscle mass in type 1 diabetes mellitus (T1DM).Materials...

ea0041gp91 | Diabetes (2) | ECE2016

Relationship between urinary metabolites and type 2 diabetes mellitus by proton nuclear magnetic resonance spectroscopy method (1H-NMR)

Ivona Stefan Lorena , Nicolescu Alina , Popa Simona , Sandu Magda , Mota Maria , Kovacs Eugenia , Deleanu Calin

Proton nuclear magnetic resonance spectroscopy (1H-NMR) was applied to investigate metabolic profile of type 2 diabetes mellitus (T2DM) patients and identify possible disorders of T2DM.We investigate the potential relationship between diabetic retinopathy (DR), diabetic neuropathy (DN), estimated glomerular filtration rate (eGFR), anthropometric indicators (body mass index (BMI), waist circumference (WC), waist to hip ratio (WHR), waist to sta...

ea0041gp92 | Diabetes (2) | ECE2016

The effect of glucose variability on microvascular complications in type 1 diabetes

Cardoso Luis , Baptista Carla , Rodrigues Dircea , Barros Luisa , Guelho Daniela , Vicente Nuno , Martins Diana , Oliveira Diana , Lages Adriana , Ventura Mara , Carrilho Francisco

Introduction: Evidence implicates oxidative stress as mediator of diabetic complications. Furthermore, glucose variability (GV) is associated with oxidative stress and inflammation; however, association between GV and diabetes complications remains to be established. Our aim was to assess GV in patients with and without microvascular complications (MVC).Methods: We analysed 2454 and 6593 h of continuous glucose monitoring of patients with type 1 diabetes...

ea0041gp93 | Diabetes (2) | ECE2016

High dose vitamin D treatment regulates the gene expression pattern in T helper cells of type 1 diabetes patients

Penna-Martinez Marissa , Hess Helen , Doring Claudia , Nejatian Nojan , Bogdanou Dimitra , Shoghi Firouzeh , Hansmann Martin-Leo , Badenhoop Klaus

Dysregulated T helper cells and vitamin D (VD) deficiency are important factors in the pathogenesis of Type 1 diabetes mellitus (T1D). Therefore, we investigated the immune effects of high dose VD-treatment on gene expression (GE) pattern in T helper cells (Th) before and after VD-therapy in patients with T1D.Methods: Seven T1D patients with 25(OH)D3 levels below 20 ng/ml received 3 months 4000 IU/d Vigantol oil. The 25(OH)D3 plasma...

ea0041gp94 | Diabetes (2) | ECE2016

Calculated creatinine clearance using the CKD-EPI-formula shows a reliable prediction and high correlation to 24-h-urine in patients with diabetes mellitus but underrates systematically potentially leading to withdrawal or no prescription of oral antidiabetics

Kloos Christof , Muller Nicolle , Anschutz Julia , Klein Friederike , Burghardt Katharina , Schmidt Sebastian , Schmidt Irina , Boer Klas , Wolf Gunter , Muller Ulrich

Introduction: To reliably assess glomerular filtration is of vital importance if oral antidiabetics are used. We compared the CKD-EPI model, a clinically established calculation model to assess creatinine clearance (CreaClear) with specimens from 24-h urine.Method: Inpatients (university hospital) with diabetes mellitus received a 24-h urine collection (24hClear) or since 2013 calculated CreaClear using CKD-EPI-formula (EPI). From 2014 to 2015 values of ...

ea0041gp95 | Diabetes (2) | ECE2016

Association between coping styles of adolescents with type 1 diabetes and metabolic control

Karachaliou Feneli , Petrou Vassilios , Drossatou Chryssa , Kaloumenou Irene , Kandyla B , Michalakos Stefanos , Karavanaki Kyriaki

Introduction: Across different chronic diseases, it has been shown that problem focused coping is associated with better adjustment. The aim of the study was to evaluate the various coping behaviors of children and adolescents with type 1 diabetes (T1DM) and their association with metabolic control and duration of disease.Methods: The study population consisted of 65 children and adolescents with T1DM (male/female: 22/43) with a mean (±S.D.</...

ea0041gp96 | Diabetes (2) | ECE2016

How soon do we achieve glycemic control after bariatric surgery? A comparative study among laparoscopic sleeve gastrectomy, mini gastric bypass, and diverted sleeve gastrectomy with ileal transposition

Celik Alper , Pouwels Sjaak , Cagiltay Eylem , Can Karaca Fatih , Buyukbozkirli Deniz , Ugale Surendra

Background: Type 2 diabetes mellitus became a global problem during recent decades, and unfortunately medical treatment fails to provide adequate control in many obese diabetics. We aimed to perform a prospective comparative cohort study to investigate how soon patients achieve glycemic control after three different surgical options (sleeve gastrectomy (SG), mini-gastric bypass (MGB), diverted sleeve gastrectomy with ileal transposition (DSIT)) within the first 30 days postope...

ea0041gp97 | Diabetes (2) | ECE2016

Real-world comparative effectiveness of liraglutide, exenatide once weekly and lisixenatide in patients with type 2 diabetes mellitus

Marco Martinez Amparo , Martinez Garcia Ana , Herranz Antolin Sandra , Lopez Gallardo Gemma , Jose Pines Corrales Pedro , Quilez Toboso Rosa , Aguirre Sanchez-Covisa Miguel , Joaquin Alfaro Jose

The improvement of glycemic control and body weight reduction by GLP-1 receptor agonist (GLP1RA) has been demostred in randomized clinical trials, but comparative studies of the efficacy of different GLP1RA in real world and clinical practice setting are limited.Objectives: To compare the efficacy of liraglutide (LIRA), exenatide once weekly (EQW), and lisixenatide (LIXI) treatment in a real-world and clinical practice setting.Meth...

ea0041gp98 | Diabetes (2) | ECE2016

Efficacy and safety of SGLT2 inhibitor Canagliflozin in the treatment of type 2 diabetes mellitus in clinical practice

Martin-Timon Iciar , Sevillano-Collantes Cristina , Moreno-Ruiz Inmaculada , Javier del Canizo-Gomez Francisco

In clinical trials, the SGLT2 inhibitor Canagliflozin inhibits renal reabsorption of glucose, increases its excretion and reduces hyperglycaemia in patients with type 2 diabetes mellitus (T2DM). The increase in glucosuria and diuresis produced, results in a reduction in weight and blood pressure (BP). Moreover, It may cause genital and urinary tract infections. However, does Canagliflozin behave in the same way in routine clinical practice?Objective: To ...

ea0041gp99 | Diabetes (2) | ECE2016

Liraglutide increases surfactant proteins (SPA & SPB) and angiotensin-converting enzymes (ACE & ACE2) expression in a rat model of acute lung injury by bleomycin

Fandino Juan , Toba Laura , Gonzalez-Nunez Maria , Diz-Chaves Yolanda , Gonzalez-Matias Lucas , Mallo Federico

Acute lung injury (ALI) is characterized by endothelial and epithelial damage, followed by inflammatory. Glucagon-like peptide-1 (GLP-1) is a gut-produced hormone with insulinotropic effects. GLP-1 receptor is expressed in the lung, and there implicated in the synthesis of surfactant proteins. We have previously shown that liraglutide (LIR), a GLP-1 receptor agonist, restores surfactant protein-B (SPB) levels, a limiting factor for survival, and also angiotensin converting enz...